IRIS
BARONE, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.066
EU - Europa 432
AS - Asia 374
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 1.887
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.047
CN - Cina 180
SG - Singapore 180
IT - Italia 73
FI - Finlandia 70
NL - Olanda 64
IE - Irlanda 63
UA - Ucraina 54
DE - Germania 52
SE - Svezia 28
GB - Regno Unito 25
CA - Canada 19
CI - Costa d'Avorio 11
IN - India 10
EU - Europa 4
IL - Israele 2
AE - Emirati Arabi Uniti 1
CZ - Repubblica Ceca 1
FR - Francia 1
IR - Iran 1
SI - Slovenia 1
Totale 1.887
Salva come PNG Salva come JPEG
Città #
Chandler 170
Singapore 141
Jacksonville 100
Santa Clara 91
Ashburn 76
Millbury 73
Princeton 70
Amsterdam 64
Nanjing 59
Boston 39
Nanchang 29
Wilmington 29
Ottawa 19
Beijing 16
Norwalk 15
Seattle 13
Naples 12
Washington 12
Boardman 11
Houston 11
Kunming 10
Rome 10
Napoli 9
Pune 8
Falls Church 7
Jiaxing 7
Shenyang 7
Los Angeles 6
Tianjin 6
Hangzhou 5
Shanghai 5
Changsha 4
Hebei 4
Kronberg 4
Ann Arbor 3
Changchun 3
Dublin 3
Indiana 3
Orange 3
Redmond 3
Campagna 2
Catania 2
Des Moines 2
Guangzhou 2
Lanzhou 2
Munich 2
New York 2
Nürnberg 2
San Mateo 2
Tel Aviv 2
Augusta 1
Bangalore 1
Boydton 1
Brno 1
Brusciano 1
Chisago City 1
Dallas 1
Helsinki 1
Islington 1
Ljubljana 1
London 1
Milan 1
Monteriggioni 1
Ospedaletto Euganeo 1
Plymouth 1
Prineville 1
Redwood City 1
Shenzhen 1
Springfield 1
Troisdorf 1
Woodbridge 1
Totale 1.201
Salva come PNG Salva come JPEG
Nome #
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial 56
Reduced striatal [123I]FP-CIT binding in SCA2 patients without parkinsonism 54
Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease 44
Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: an FP-CIT SPECT study. 41
Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients 41
Amitriptyline as a prophylactic for migraine in children. 40
Dopamine mediated responses in 6-OH-DA lesioned rats involve changes of the signal transduction. 40
Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. 40
Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK-2. 38
Behavioural sensitization in 6-OHDA lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB-related and JunD-related proteins 37
Dopa-responsive pseudo-orthostatic tremor in parkinsonism. 37
Freezing of gait and executive functions in patients with Parkinson's disease. 37
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 36
Nitrite- and peroxide-dependent oxidation pathways of dopamine: 6-nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide-induced neurotoxicity in neuronal degeneration 35
The status of dopamine nerve terminals in Parkinson\'s disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. 34
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. 34
Depression rating scales in Parkinson's disease: critique and recommendations. 33
A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. 33
Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. 33
Dopamine agonist-based strategies in the treatment of Parkinson's disease. 31
Is arginine test a reliable tool for differential diagnosis of multiple system atrophy? 31
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. 31
Dopamine receptor agonists and depression in Parkinson's disease. 30
Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. 29
No evidence of association between CAG expansions and essential tremor in a large cohort of italian patients 28
Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. 28
Neurotransmission in Parkinson's disease: beyond dopamine. 28
Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. 28
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. 28
No evidence of association between CAG expansions and essential tremor in a large cohort of italian patients 27
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. 27
Linkage exclusion in Italian families with hereditary essential tremor. 27
Pergolide monotherapy in the treatment of early PD. A randomized, controlled study. 26
The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms 26
Apoptotic mechanisms in mutant LRRK2-mediated cell death. 26
Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. 26
Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. 26
Perspectives on recent advances in the understanding and treatment of Parkinson's disease. 25
Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion 25
Headache in children, an epidemiological study. 24
Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. 24
Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. 24
Nitric oxide-hemoglobin interaction: a new biochemical hypothesis for signal changes in fMRI 24
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. 23
The PRIAMO study: background, methods and recruitment. 23
The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. 22
Red flags for multiple system atrophy. 22
Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. 22
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. 21
MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. 21
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. 21
Clinical and neurological abnormalities in adult celiac disease. 21
Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. 21
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. 21
Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. 21
Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. 20
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. 20
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). 20
HOMER1 promoter analysis in parkinson's disease: association study with psychotic symptoms 20
Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. 20
PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. 19
RNA analysis of consensus sequence splicing mutations: implications for the diagnosis of Wilson disease. 19
HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms. 18
Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test 17
The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. 17
Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. 16
The FRAGAMP study: environmental and genetic factors inParkinson's disease, methods and clinical features. 16
Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. 15
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. 14
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. 14
null 12
Totale 1.928
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.906
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.906
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202087 0 0 0 0 11 0 1 1 1 9 17 47
2020/2021146 1 11 19 11 11 45 11 2 13 2 19 1
2021/2022319 3 0 0 4 0 9 1 12 67 12 52 159
2022/2023410 73 35 17 25 46 33 0 38 57 66 16 4
2023/2024321 7 38 32 35 27 53 2 32 0 10 73 12
2024/2025284 101 82 6 9 86 0 0 0 0 0 0 0
Totale 1.928